JoVE   
You do not have subscription access to articles in this section. Learn more about access.

  JoVE Biology

  
You do not have subscription access to articles in this section. Learn more about access.

  JoVE Neuroscience

  
You do not have subscription access to articles in this section. Learn more about access.

  JoVE Immunology and Infection

  
You do not have subscription access to articles in this section. Learn more about access.

  JoVE Clinical and Translational Medicine

  
You do not have subscription access to articles in this section. Learn more about access.

  JoVE Bioengineering

  
You do not have subscription access to articles in this section. Learn more about access.

  JoVE Applied Physics

  
You do not have subscription access to articles in this section. Learn more about access.

  JoVE Chemistry

  
You do not have subscription access to articles in this section. Learn more about access.

  JoVE Behavior

  
You do not have subscription access to articles in this section. Learn more about access.

  JoVE Environment

|   

JoVE Science Education

General Laboratory Techniques

You do not have subscription access to videos in this collection. Learn more about access.

Basic Methods in Cellular and Molecular Biology

You do not have subscription access to videos in this collection. Learn more about access.

Model Organisms I

You do not have subscription access to videos in this collection. Learn more about access.

Model Organisms II

You do not have subscription access to videos in this collection. Learn more about access.

Essentials of
Neuroscience

You do not have subscription access to videos in this collection. Learn more about access.

 JoVE Biology

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase

1

1Department of Cell Biology and Virology, Heinrich-Pette-Institute for Experimental Virology and Immunology, University of Hamburg

Article
    Downloads Comments Metrics

    You must be subscribed to JoVE to access this content.

    This article is a part of   JoVE Biology. If you think this article would be useful for your research, please recommend JoVE to your institution's librarian.

    Recommend JoVE to Your Librarian

    Current Access Through Your IP Address

    You do not have access to any JoVE content through your current IP address.

    IP: 54.161.166.171, User IP: 54.161.166.171, User IP Hex: 916563627

    Current Access Through Your Registered Email Address

    You aren't signed into JoVE. If your institution subscribes to JoVE, please or create an account with your institutional email address to access this content.

     

    Summary

    Current HIV-1 strategies act to suppress the viral life cycle but do not effectively eradicate infection. Here, we demonstrate that an engineered recombinase can efficiently excise integrated HIV-1 proviral DNA from the genome of infected cells.

    Date Published: 6/16/2008, Issue 16; doi: 10.3791/793

    Cite this Article

    Hauber, J. Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase. J. Vis. Exp. (16), e793, doi:10.3791/793 (2008).

    Abstract

    HIV-1 integrates into the host chromosome of infected cells and persists as a provirus flanked by long terminal repeats. Current treatment strategies primarily target virus enzymes or virus-cell fusion, suppressing the viral life cycle without eradicating the infection. Since the integrated provirus is not targeted by these approaches, new resistant strains of HIV-1 may emerge. Here, we report that the engineered recombinase Tre (see Molecular evolution of the Tre recombinase , Buchholz, F., Max Planck Institute for Cell Biology and Genetics, Dresden) efficiently excises integrated HIV-1 proviral DNA from the genome of infected cells. We produced loxLTR containing viral pseudotypes and infected HeLa cells to examine whether Tre recombinase can excise the provirus from the genome of HIV-1 infected human cells. A virus particle-releasing cell line was cloned and transfected with a plasmid expressing Tre or with a parental control vector. Recombinase activity and virus production were monitored. All assays demonstrated the efficient deletion of the provirus from infected cells without visible cytotoxic effects. These results serve as proof of principle that it is possible to evolve a recombinase to specifically target an HIV-1 LTR and that this recombinase is capable of excising the HIV-1 provirus from the genome of HIV-1-infected human cells.

    Before an engineered recombinase could enter the therapeutic arena, however, significant obstacles need to be overcome. Among the most critical issues, that we face, are an efficient and safe delivery to targeted cells and the absence of side effects.

    Protocol

    Please view related videos entitled Principles of Site-Specific Recombinase (SSR) Technology and Molecular Evolution of the Tre Recombinase for more information about site-specific recombination and engineering the site-specificity of recombinase enzymes.

    Subscription Required. Please recommend JoVE to your librarian.

    Disclosures

    The authors have nothing to disclose.

    Comments

    10 Comments

    Please this must be in clinical trials asap..  
    Reply

    Posted by: AnonymousJune 24, 2008, 7:26 PM

    Moving faster with recombinase. To tell the truth i don' t trust completely in the results of the research, any kind of research, humans trial included. Kp-1461 has been halted almost at the end of phase ² humans trial.. and now seems that kp-1461 can not work in vitro too.. The koronispharma managers have to pay for this.. A LOT OF MONEY.
    Reply

    Posted by: AnonymousJune 25, 2008, 8:56 AM

    how can I download a video protocol in my flash disc?  
    Reply

    Posted by: AnonymousSeptember 20, 2008, 4:36 PM

    Dear Anonymous, please feel free to contact us at support@jove.com and we could discuss your problem.
    Reply

    Posted by: AnonymousOctober 6, 2008, 6:34 PM

    How can I get in touch with doctor Joachim Hauber? I am HIV positive, there isn´t a single day ever since I was diagnosed this disease that I don´t feel like my life just ended. I would do anything to get cured.
    Reply

    Posted by: AnonymousOctober 20, 2008, 1:37 PM

    Reply

    Posted by: AnonymousNovember 3, 2008, 8:41 AM

    Interesting presentation on remarkable research. Worthy of further discussion
    Reply

    Posted by: AnonymousFebruary 23, 2009, 1:48 PM

    Have you sequenced the host cell genome in the wild type control vs. the HIV-1 infected vs Tre recombinase cells to
    definitively show where the HIV-1 genome is inserting, and that it is removed?
    Reply

    Posted by: Douglas C.October 21, 2009, 9:41 AM

    why can't i get an update on this work?? i have looked everywhere. it has gotten so little publicity..i dont get it
    Reply

    Posted by: AnonymousJune 25, 2010, 1:04 AM

    hi
    i need full text this article
    plz
    tanx
    Reply

    Posted by: AnonymousOctober 10, 2010, 4:23 PM

    Post a Question / Comment / Request

    You must be signed in to post a comment. Please or create an account.

    Metrics

    Waiting
    simple hit counter